Activation of peroxisome proliferator-activated receptor γ impedes Porphyromonas gingivalis lipopolysaccharide interference with salivary mucin synthesis through phosphatidylinositol 3-kinase/ERK pathway

Journal of Physiology and Pharmacology

Volumn 54, Issue 1, 2003, Pages 3-15

  Slomiany, B L ^a,b   Slomiany, A ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b RUTGERS SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

NOS 2; P. gingivalis LPS; PPAR activation: ERK and P13K; Salivary mucin synthesis

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BACTERIUM LIPOPOLYSACCHARIDE; CIGLITAZONE; GLYCOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; WORTMANNIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; INFLAMMATION; MOUTH MUCOSA; NONHUMAN; PERIODONTITIS; PORPHYROMONAS GINGIVALIS; PROTEIN SYNTHESIS; RAT; SUBLINGUAL GLAND;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; LIPOPOLYSACCHARIDES; MITOGEN-ACTIVATED PROTEIN KINASES; MUCINS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PORPHYROMONAS GINGIVALIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SUBLINGUAL GLAND; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 0037346352     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Fox CH. New considerations in the prevalence of periodontal disease. Curr Opin Den 1992; 2: 5-11.
2. Ximenez-Fyvie LA, Haffajee AD, Socransky S. Microbial composition of supra- and subgingival plaque in subjects with adult periodontitis. J Clin Microbiol 2000; 27: 722-732.
3. Nonnenmacher C, Mutters R, deJacoby, LF. Microbiological characteristics of subgingival microbiota in adult periodontitis, localized juvenile periodontitis and rapidly progressive periodontitis subjects. Clin Microbiol Infect 2001; 7: 213-221.
4. O'Brien-Simpson NM, Paolini RA, Hoffmann B, et al. Role of RgpA, RgpB, and Kgp proteinases in virulence of Porphyromonas gingivalis W50 in a murine lesion model. Infect Immun 2001; 69: 7527-7534.
5. Slomiany BL, Murty VLN, Piotrowski J, Liau YH, Slomiany A. Glycosulfatase activity of Porphyromonas gingivalis a bacterium associated with periodontal disease. Biochem Mol Biol Int 1993; 29: 973-980.
6. Potempa J, Babula A, Travis J. Role of bacterial proteinases in matrix destruction and modulation of host responses. Periodontol 2000; 24: 153-192.
7. Wang PL, Sato K, Oido M, et al. Involvement of CD14 on human gingival fibroblasts in Porphyromonas gingivalis lipopolysaccharide-mediated interleukin-6 secretion. Arch Oral Biol 1998; 43: 687-694.
8. Wang PL, Ohura K. Porphyromonas gingivalis lipopolysaccharide signaling in gingival fibroblasts - CD14 and Toll-like receptors. Crit Rev Oral Biol Med 2002; 13: 132-142.
9. Slomiany BL, Murty VLN, Piotrowski J, Slomiany A. Salivary mucins in oral mucosal defense. Gen Pharmac 1996; 27: 761-771.
10. Slomiany A, Nishikawa H, Slomiany BL. Screening and modulation of extracellular signals by mucous barrier. Serum glycosylphosphatidylinositol phospholipase D (GP1-PLD) releases protective mucous barrier from oral mucosa. J Physiol Pharmacol 2002; 53: 21-38.
11. Slomiany BL, Slomiany, A. Porphyromonas gingivalis interferes with salivary mucin synthesis through inducible nitric oxide synthase activation of ERK and p38 kinase. Biochem Biophys Res Commun 2002; 297: 1149-1153.
12. Ono K, Han J. The p38 signal transduction pathway activation and function. Cell Signal 2000; 12: 1-13.
13. Ma W, Lim W, Gee K, et al. The p38 mitogen-activated pathway regulates interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J Biol Chem 2001; 276: 13664-13674.
14. Da Silva J, Pierrat B, Mary JL, Lessauer W. Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitric oxide synthase expression in mouse astrocytes. J Biol Chem 1997; 272: 28373-28380.
15. Kim SJ, Ju JW, Oh C.D, et al. ERK-1/2 and p38 kinase oppositely regulate nitric oxide-induced apoptosis of chondrocytes in association with p53, caspase-3 and differentiation status. J Biol Chem 2002; 277: 1332-1339.
16. Watters JT, Sommer JA, Pjeiffer ZA, et al. A differential role for mitogen-activated protein kinase in lipopolysaccharide signaling. J Biol Chem 2002; 277: 9077-9087.
17. Slomiany BL, Slomiany A. Nitric oxide interferes with salivary mucin synthesis: involvement of ERK and p38 mitogen-activated protein kinase. J Physiol Pharmacol 2002; 53: 325-336.
18. Park YC, Lee CH, Kang, HS, Chung HT, Kim HD. Wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase, enhances LPS-induced NO production from murine peritoneal macrophages. Biochem Biophys Res Commun 1997; 240: 692-696.
19. Guha M, Mackman N. The phosphatidylinositol 3-kinase-Act pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 2002; 277: 32124-32132.
20. 12,14-prostaglandin J, and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J Biol Chem 2001; 276: 48950-48955.
21. Slomiany BL, Liau, YH, Li Q, Fekete Z, Slomiany, A. Role of sulfation in post-translational processing of salivary mucins. Arch Oral Biol 1991; 36: 785-790.
22. Slomiany BL, Sengupta S, Piotrowski J, Shovlin FE, Slomiany A. Inhibition of bovine gingival laminin receptor by bacterial lipopolysaccharide. Archs Oral Biol 1991; 36: 341-346.
23. Slomiany BL, Slomiany A. Nonsteroidal anti-inflammatory drugs impair oral mucosal repair by eliciting disturbances in endothelin-converting enzyme-1 and constitutive nitric oxide synthase. J Physiol Pharmacol 2001; 52: 81-92.
24. Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Anal Biochem 1982; 126: 131-138.
25. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activatcd receptor γ ligands are potent inhibitors of angiogenesis. J Biol Chem 1999; 274: 9116-9121.
26. Inoue H, Tanabe T, Umesone K. Feedback control of cyclooxygenase expression through PPARγ. J Biol Chem 2000; 275: 28028-28032.
27. Nakajima A, Wada K, Miki H, et al. Endogenous PPARγ mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 2001; 120: 460-469.
28. Gupta RA, Polk DB, Krishna U, et al. Activation of peroxisome proliferator-activated receptor γ suppresses nuclear factor κB-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J Biol Chem 2001; 276: 31059-31066.
29. Slomiany BL, Slomiany A. Suppression of gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide by peroxisome proliferator-activated receptor γ activation. IUBMB Life 2002; 53: 303-308.
30. Slomiany BL, Slomiany A. Activation of peroxisome proliferator-activated receptor γ suppresses inducible cyclooxygenase and nitric oxide synthase during oral mucosal ulcer healing. J Physiol. Pharmacol 2002; 53: 159-169.
31. Miura K, MacGlashan DW. Phosphatidylinositol-3 kinase regulates p21ras activation during IgE-mediated stimulation of human basophilis. Blood 2000; 96: 2199-2205.
32. Tanaka T, Kohno H, Yoshitani S, et al. Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001; 61: 2424-2428.